Briefly, this study illustrates that OSBPL2 defect collaborates with ECM Collagen I to promote colorectal tumor growth and metastasis through two independent pathways and provides the basis for appropriate therapy using ERK and PARP1 inhibitors to treat OSBPL2Low CRC. Here, PARP1 is linked to colorectal carcinoma.